China's Ambitious Biotechnology Strategy Raises Concerns for US Leadership
China's Biotechnology Push
Representational Image
Washington, June 12: China is aggressively pursuing dominance in the biotechnology sector, implementing numerous policies suggested by a US national security commission. This trend raises alarms that the United States may relinquish its longstanding leadership in a field increasingly recognized as vital for both economic and military strength.
A recent report published by the National Security Commission on Emerging Biotechnology (NSCEB) indicates that the Chinese Communist Party (CCP) is making significant strides in biotechnology across five critical areas outlined in the commission's action plan from April 2025: national strategy, regulation, infrastructure, investment, and data management.
The analysis suggests that Beijing is outpacing Washington in converting its biotechnology goals into actionable government policies and industrial capabilities.
NSCEB Chair Senator Todd Young remarked, "China's biotech strategy is evident, resembling a familiar playbook—dominate the market, scale the technology, and then disrupt supply chains to secure strategic advantages."
He further noted, "The Chinese government is utilizing biotechnology policies more effectively than the US, and we are beginning to lag in innovation and scaling up operations."
The commission highlighted that China has prioritized biotechnology for the past twenty years, reaffirming its commitment in the 2026 Five-Year Plan, which designates biomedicine, biomanufacturing, brain-computer interface technologies, and pharmaceuticals as strategic sectors, alongside artificial intelligence and quantum computing.
In contrast, the United States currently lacks a cohesive national biotechnology strategy, although bipartisan lawmakers have introduced legislation in 2025 aimed at synchronizing biotechnology policies at the federal level.
The report also pointed out China's regulatory advantages, noting that reforms over the last decade have established a dual-track system for drugs and medical products, expediting approvals and enabling researchers to gather preliminary human data more swiftly.
Consequently, by 2024, China led globally in the number of annual clinical trials initiated, with several US pharmaceutical firms now conducting first-in-human trials in China.
The report also highlighted disparities in manufacturing capabilities. While Congress has allocated funds for bioindustrial facilities under the BioMADE program, none of the three announced facilities are operational yet.
In contrast, China has formed public-private partnerships with 43 companies in 2025 to establish biomanufacturing pilot plants across the nation.
The commission noted Beijing's extensive use of government-backed investment vehicles to bolster strategic industries and its initiatives to treat biological data as a national asset for training AI systems and enhancing biotechnology development.
Senator Young stated, "US policymakers have acted on more than half of the NSCEB's recommendations over the past year, but there is still much work to be done. Some of our most ambitious proposals—ranging from regulatory streamlining to manufacturing infrastructure—have yet to be realized. This is a race we cannot afford to lose, and we urge prompt action on the NSCEB's roadmap to maintain America's leadership in global biotechnology."
The report also cautioned that biotechnology has significant national security implications, indicating that China aims to integrate biotechnology into its military capabilities, potentially enhancing its military strength.
Biotechnology has become a crucial battleground in the broader US-China rivalry over advanced technologies. Alongside semiconductors, artificial intelligence, and quantum computing, both governments increasingly view biotechnology as essential for future economic growth, healthcare advancements, and national security.
The NSCEB was established by Congress to evaluate the national security ramifications of emerging biotechnology and to propose policies that would bolster US competitiveness. Its 2025 action plan called for a unified national strategy, expedited regulations, expanded manufacturing capabilities, increased investment, and improved biological data infrastructure.